title: Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy.
abstract: Mastocytosis is a clonal disease derived from hematopoietic bone marrow progenitor cells. Clinical manifestations of the disease vary greatly depending on tissue involvement. Omalizumab is a recombinant humanized monoclonal anti-IgE antibody licensed in the treatment of asthma with increasing reports of clinical eficiency in other allergic diseases. We describe a case of a patient with mastocytosis responsive clinically and patho-physiologically after anti-IgE treatment.
authors.affiliation: Allergy and Clinical Immunology Department, 401 General Military Hospital of Athens, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Paraskevopoulos
authors.forename: E
authors.initials: E
authors.lastname: Sifnaios
authors.forename: K
authors.initials: K
authors.lastname: Christodoulopoulos
authors.forename: F
authors.initials: F
authors.lastname: Mantopoulou
authors.forename: M
authors.initials: M
authors.lastname: Papakonstantis
authors.forename: D
authors.initials: D
authors.lastname: Sabaziotis
mesh_terms: D000328:Adult; D000707:Anaphylaxis / Q000188:drug therapy* / Q000276:immunology; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008407:Mast Cells / Q000187:drug effects* / Q000276:immunology; D008415:Mastocytosis / Q000188:drug therapy* / Q000276:immunology; D000069444:Omalizumab; D012867:Skin / Q000187:drug effects* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; C026408:anti-IgE antibodies; D000069444:Omalizumab